MAP1LC3B and cancer: The association of high LC3B expression with aggressive disease and poor outcomes was repeatedly reported in other cancer types, including gastric adenocarcinoma [50,51,52], colorectal cancers [53,54,55,56], melanoma [22], astrocytoma [57], esophageal cancer [58], oral squamous cell carcinoma [59] and hepatocellular carcinoma [60].